The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

The Macula Society Annual Meeting is a highly selective, invitation-only forum where internationally recognized retinal experts convene to present and critically evaluate emerging clinical data and ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

In this Healio Video Perspective from Retina 2026, Ehsan Rahimy, MD, discusses the potential of IL-6 inhibition for the ...

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the anti-VEGF group. Visual acuity and central macular thickness improved in patients ...

Expert Rev Ophthalmol. 2013;8(5):475-484. Together, these preclinical data indicate that both antibody and small kinase-based VEGF/PDGF antagonists are effective in animal models of pathologic ocular ...

Alternative regimens of anti-VEGF therapy for neovascular AMD, variable treatment in particular, have become the de facto clinical practice. Their wide adoption is based on a tacit belief in their ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...